Study on Enzalutamide and Prostate Cancer Survival Outcomes

Overview of Prostate Cancer Treatment

A recent study explored the impact of Enzalutamide, a novel drug therapy for prostate cancer, on survival outcomes. Standard treatment for prostate cancer typically involves testosterone suppression as the first-line approach, often supplemented with a nonsteroidal antiandrogen drug to lower testosterone levels. However, some patients develop resistance to these nonsteroidal antiandrogens, diminishing their effectiveness against the disease.

Enzalutamide’s Role in Overcoming Resistance

Enzalutamide is specifically designed to address this resistance issue. While previous studies have indicated its benefits for prostate cancer patients who no longer respond to hormone therapies, its efficacy for those still undergoing hormone treatments had not been thoroughly investigated.

The ENZAMET Trial

To examine whether enzalutamide enhances survival in hormone-sensitive prostate cancer patients, researchers in Australia initiated the ENZAMET trial. The findings were published in The New England Journal of Medicine. The study enrolled 1,125 males diagnosed with advanced hormone-sensitive prostate cancer, who were randomized to receive either enzalutamide or a standard nonsteroidal antiandrogen drug, alongside continuous testosterone suppression therapy.

Study Methodology

Participants continued their assigned treatments until either disease progression occurred or side effects necessitated discontinuation. Physicians had the discretion to include docetaxel or abiraterone in the treatment regimen, as prior studies indicated these drugs could improve survival when used in conjunction with testosterone suppression.

Key Findings

The primary outcome measured was overall survival. After three years of follow-up, results indicated that the enzalutamide group experienced significantly greater overall survival compared to the standard care group. Specifically, three-year overall survival estimates were 80% in the enzalutamide group versus 72% in the standard care group. These results remained consistent even after adjusting for potential influencing factors, such as geographical region, disease burden, and existing medical conditions.

Adverse Effects and Considerations

Additionally, enzalutamide showed superior results in prolonging the time without disease progression. However, the study also reported a higher incidence of adverse effects, including seizures and fatigue, associated with enzalutamide compared to standard treatment. These side effects are known risks tied to enzalutamide use.

Conclusion and Future Research

The ENZAMET trial’s findings suggest that incorporating enzalutamide into testosterone suppression therapy for advanced hormone-sensitive prostate cancer can lead to improved overall survival within three years. Nevertheless, further research is necessary to assess the long-term benefits beyond this period.

References

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., . . . Sweeney, C. J. (2019). Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine. doi:10.1056/nejmoa1903835

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer. (2019, June 02). Retrieved from https://www.eurekalert.org/pub_releases/2019-06/dci-eis053019.php

Related Topics

– Is there a prostate cancer prevention diet?
– Significant developments in a new urine test for prostate cancer
– A urine test for prostate cancer that can be done at home
– Possible link between prostate cancer and fatherhood through assisted reproduction
– Can family history explain the link between breast cancer and prostate cancer?
– Gene therapy for prostate cancer is more effective when combined with chemotherapy, study finds